KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) FCF Margin (2016 - 2025)

Historic FCF Margin for Sarepta Therapeutics (SRPT) over the last 12 years, with Q2 2025 value amounting to 37.56%.

  • Sarepta Therapeutics' FCF Margin rose 414800.0% to 37.56% in Q2 2025 from the same period last year, while for Sep 2025 it was 27.59%, marking a year-over-year increase of 10900.0%. This contributed to the annual value of 18.02% for FY2024, which is 284000.0% up from last year.
  • According to the latest figures from Q2 2025, Sarepta Therapeutics' FCF Margin is 37.56%, which was up 414800.0% from 559.9% recorded in Q1 2025.
  • Over the past 5 years, Sarepta Therapeutics' FCF Margin peaked at 37.56% during Q2 2025, and registered a low of 559.9% during Q1 2025.
  • Moreover, its 5-year median value for FCF Margin was 41.17% (2022), whereas its average is 69.82%.
  • Over the last 5 years, Sarepta Therapeutics' FCF Margin had its largest YoY gain of 1243200bps in 2021, and its largest YoY loss of -6814000bps in 2021.
  • Sarepta Therapeutics' FCF Margin (Quarter) stood at 15.65% in 2021, then crashed by -148bps to 38.83% in 2022, then skyrocketed by 52bps to 18.57% in 2023, then surged by 144bps to 8.2% in 2024, then skyrocketed by 358bps to 37.56% in 2025.
  • Its FCF Margin was 37.56% in Q2 2025, compared to 559.9% in Q1 2025 and 8.2% in Q4 2024.